Modulation of the functions of myeloid‐derived suppressor cells : a new strategy of hydrogen sulfide anti‐cancer effects
Open Access
- 7 August 2019
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (4) , 884-897
Abstract
Background and Purpose: Myeloid‐derived suppressor cells (MDSCs) represent a major obstacle to cancer treatment, as they negatively regulate anti‐tumour immunity through the suppression of tumour‐specific T lymphocytes. Thus, the efficacy of immunotherapies may be improved by targeting MDSCs. In this study, we assessed the ability of hydrogen sulfide (H2S), a gasotransmitter whose anti‐cancer effects are well known, to inhibit the accumulation and immunosuppressive functions of MDSCs in melanoma.Experimental Approach: Effects of H2S on the host immune response to cancer were evaluated using an in vivo syngeneic model of murine melanoma. B16F10‐melanoma‐bearing mice were treated with the H2S donor, diallyl trisulfide (DATS) and analysed for content of MDSCs, dendritic cells (DCs) and T cells. Effects of H2S on expression of immunosuppressive genes in MDSCs and on T cell proliferation were evaluated.Key Results: In melanoma‐bearing mice, DATS inhibited tumour growth, and this effect was associated with a reduction in the frequency of MDSCs in the spleen, in the blood as well as in the tumour micro‐environment. In addition, we found that CD8+ T cells and DCs were increased. Furthermore, DATS reduced the immuno‐suppressive activity of MDSCs, restoring T cell proliferation.Conclusions and Implications: The H2S donor compound, DATS, inhibited the expansion and the suppressive functions of MDSCs, suggesting a novel role for H2S as a modulator of MDSCs in cancer. Therefore, H2S donors may provide a novel approach for enhancing the efficacy of melanoma immunotherapy.Linked Articles: This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetocKeywords
Funding Information
- Faculty of Medicine, Prince of Songkla University (2012WBSSY4 005)
This publication has 37 references indexed in Scilit:
- THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: EnzymesBritish Journal of Pharmacology, 2017
- Improving cancer immunotherapy by targeting the STATe of MDSCsOncoImmunology, 2016
- Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug ResistancePLOS ONE, 2013
- Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patientsCancer Immunology, Immunotherapy, 2013
- Redox biology of hydrogen sulfide: Implications for physiology, pathophysiology, and pharmacologyRedox Biology, 2013
- A tale of two gases: NO and H2S, foes or friends for life?Redox Biology, 2013
- Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivoBiochemical Pharmacology, 2012
- The Slow-Releasing Hydrogen Sulfide Donor, GYY4137, Exhibits Novel Anti-Cancer Effects In Vitro and In VivoPLOS ONE, 2011
- Redox Remodeling as an Immunoregulatory StrategyBiochemistry, 2010
- Biosynthesis and biological properties of compounds containing highly reactive, reduced sulfane sulfur.2002